The U.S. market is currently experiencing heightened volatility, with major indices like the Dow Jones and Nasdaq Composite facing declines due to renewed trade tensions following President Trump's recent tariff threats against the EU and Apple. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability amidst shifting economic policies and global trade uncertainties.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Bit Digital (NasdaqCM:BTBT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Bit Digital, Inc., along with its subsidiaries, operates in the bitcoin mining industry and has a market capitalization of $502.52 million.
Operations: The company is involved in bitcoin mining, focusing on generating revenue through the production of bitcoin. With a market capitalization of $502.52 million, its business model revolves around leveraging its mining operations to capitalize on the cryptocurrency market.
Despite recent setbacks, Bit Digital's aggressive expansion into AI infrastructure, highlighted by its new data center in Quebec and a significant partnership with Cerebras Systems, underscores its strategic pivot towards high-growth sectors. This move is particularly notable as the company navigates through a challenging phase marked by a substantial net loss of $57.71 million in Q1 2025 and a sharp revenue drop from the previous year. However, with an expected annual profit growth of 103% and revenue growth forecasts outpacing the market at 34.6%, Bit Digital is positioning itself to capitalize on burgeoning tech trends, albeit amidst financial volatility and shareholder dilution concerns from recent equity offerings.
- Click here and access our complete health analysis report to understand the dynamics of Bit Digital.
Gain insights into Bit Digital's historical performance by reviewing our past performance report.
ADMA Biologics (NasdaqGM:ADMA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of $4.80 billion.
Operations: ADMA Biologics generates revenue primarily from its ADMA Biomanufacturing segment, which accounts for $449.41 million, and its Plasma Collection Centers contributing $9.83 million.
ADMA Biologics has demonstrated robust growth with a 20.8% forecast in annual earnings and an 18.6% increase in revenue per year, outpacing the US market average of 14.3% and 8.6%, respectively. This growth is supported by strategic advancements, such as the FDA-approved yield enhancement process that boosts production by approximately 20%. Additionally, the company's proactive financial strategy is evident from its recent share repurchase program valued at $500 million and upward revisions in revenue expectations to over $625 million by 2026, reflecting strong operational performance and market confidence.
- Dive into the specifics of ADMA Biologics here with our thorough health report.
Evaluate ADMA Biologics' historical performance by accessing our past performance report.
Geron (NasdaqGS:GERN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Geron Corporation is a commercial-stage biopharmaceutical company dedicated to developing therapeutic products for oncology, with a market capitalization of $853.47 million.
Operations: Geron Corporation generates revenue primarily from the development of therapeutic products for oncology, amounting to $116.29 million. The focus on oncology therapeutics defines its business model and revenue stream.
Despite Geron's current unprofitability, its revenue is projected to grow at an impressive rate of 35.9% annually, outstripping the US market average of 8.6%. This growth trajectory is underpinned by a significant increase in R&D spending aimed at developing innovative biotech solutions, reflecting a strategic commitment to long-term value creation through scientific advancement. Recent financial results underscore this potential: Q1 2025 revenue surged to $39.6 million from just $0.304 million the previous year, alongside a reduction in net loss from $55.39 million to $19.84 million year-over-year, signaling improving operational efficiency and market adaptation despite ongoing legal challenges and leadership transitions that could influence future performance and investor sentiment.
- Get an in-depth perspective on Geron's performance by reading our health report here.
Explore historical data to track Geron's performance over time in our Past section.
Taking Advantage
- Delve into our full catalog of 237 US High Growth Tech and AI Stocks here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Geron might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com